

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

04 May 2023 (04.05.2023)



(10) International Publication Number

WO 2023/073722 A1

(51) International Patent Classification:

A61N 1/04 (2006.01) A61N 1/36 (2006.01)
A61N 1/05 (2006.01) A61B 18/14 (2006.01)
A61N 1/32 (2006.01) A61B 18/08 (2006.01)

(21) International Application Number:

PCT/IL2022/051156

(22) International Filing Date:

01 November 2022 (01.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/273,961 31 October 2021 (31.10.2021) US

(71) Applicant: SYNAPSTIM [IL/IL]; David Hamelech St 106,
4660907 Herzedia (IL).

(72) Inventors: SOLOMON, Sasi; David Hamelech St 106,
Herzlia (IL). SIMON, Semion; Tishre 11/11, 4252471 Ne-
tanya (IL).

(74) Agent: SPUNGIN, Ben; Alexandroni, 18, 93764 Petah
Tikva (IL).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with information concerning request for restoration of the
right of priority in respect of one or more priority claims
(Rules 26bis.3 and 48.2(b)(vii))

(54) Title: SYSTEM AND METHOD FOR ELECTRICALLY STIMULATING TISSUE

(57) Abstract: A system and method for electrical stimulation of a body tissue. An array of microneedles, formed from an electrically conductive material are adapted for puncturing a surface of the tissue. A processing unit is configured to determine from a signal when the microneedles in the microneedle array are in a predetermined position in the tissue or when tissue surrounding one or more microneedles has been ablated.



WO 2023/073722 A1

SYSTEM AND METHOD FOR ELECTRICALLY STIMULATING TISSUE

FIELD OF THE INVENTION

- 5 The present invention relates to medical devices and more specifically to such devices for electrical stimulation of body tissues.

BACKGROUND

Electrical stimulation of body tissues is used for treatment of chronic and acute
10 medical conditions and can be carried out using implantable or surface electrodes. Implanted electrodes are typically used to directly stimulate tissue at a desired site. While effective in stimulating target tissues, implanted electrodes exhibit significant drawbacks such as implant site infections, electrode failure and electrode displacement.

15 Despite improvements to implantable electrode technologies in recent years, transcutaneous electrical stimulation (TES) is still the most frequently applied approach for stimulating muscle and nerve tissue that are close to the skin surface and is commonly used for relieving pain, for rehabilitation and for treating migraine. TES utilizes surface electrodes rather than implanted electrodes for delivering an electrical
20 signal to tissue such as muscle or nerve tissue. Surface electrodes do not require an implantation procedure and hence avoid some of the drawbacks of implanted electrodes. While transcutaneous electrodes overcome some of the above mentioned drawbacks of implantable electrodes, their positioning on the skin surface often diverts the electric signal from the target tissue (e.g., nerves, muscle) and forces the
25 electrical signal to travel through electrically resistive tissue (e.g., keratinized layer of the skin). These drawbacks of surface electrodes often make them unsuitable for stimulation of deep tissue such as the tibial nerve for applications such as overactive bladder or the vagus nerve for applications such as autoimmune and inflammatory diseases.

30 The largest drawback to using surface electrodes arises from the fact that for many applications, surface electrodes are too far from the tissue to be stimulated to be effective. In the case of surface skin electrodes, the electrical signal will travel through superficial layer of the skin such as the keratinized skin layer where the

majority of the signal is dissipated, and the electrical signal will not reach target tissue (nerve or muscle) in the deeper layers.

US Patent No. 10,688,301 discloses a TES system that employs a microneedle array for forming electrically conductive micropores through a tissue surface. It was
5 found that the formation of micropores in the superficial layers of the skin enhances the penetration of the electrical stimulation into the deeper layers of the tissue. thus overcoming some of the aforementioned drawbacks of standard surface electrode systems. While the system disclosed in US Patent No. 10,688,301 substantially improves TES, there still remains a need for a system and method for electrically
10 stimulating tissue using surface electrodes.

SUMMARY OF THE INVENTION

15

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable
20 methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Implementation of the method and system of the present invention involves performing or completing selected tasks or steps manually, automatically, or a
25 combination thereof. Moreover, according to actual instrumentation and equipment of preferred embodiments of the method and system of the present invention, several selected steps could be implemented by hardware or by software on any operating system of any firmware or a combination thereof. For example, as hardware, selected steps of the invention could be implemented as a chip or a circuit. As software,
30 selected steps of the invention could be implemented as a plurality of software instructions being executed by a computer using any suitable operating system. In any case, selected steps of the method and system of the invention could be described as

being performed by a data processor, such as a computing platform for executing a plurality of instructions.

In one of its aspects, the present invention provides a system for electrical stimulation of a body tissue. In one of its embodiments, the system of the invention
5 includes an applicator including an array of two or more microneedles. The microneedles are made from an electrically conductive material such as stainless steel, and, in addition to being able to puncture the tissue surface and enter the tissue, the microneedles also function as electrodes.

The system may further include a control unit, which includes a processing
10 unit, a signal generator, power unit and a switching circuit. The processing unit controls the switching circuit, to intermittently connect the various electrodes of the system to poles of the signal generator during the various stages of the treatment

The system may further comprises a force detector that may be incorporated into the applicator. The force detector detects pressure applied to the tissue surface by
15 the tips of the microneedles as the applicator is pressed into the tissue surface during penetration of the microneedles into the tissue.

The system further comprises one or more surface electrodes. The processing unit also controls the switching circuit to intermittently connect two or more surface electrodes to the poles of the power unit and/or the signal generator.

20 In use, the applicator is applied to a first tissue surface overlying a deeper second tissue region to be treated. The second tissue may be, for example, a nerve or nerve tissue. For example, the applicator can be placed on the neck of an individual over the vagus nerve in a treatment for stimulating the vagus nerve. As pressure is applied by the applicator, the force detector detects a pressure applied to the tissue
25 surface and generates an electrical signal indicative of the pressure that is input to the processing unit. The processing unit constantly monitors or is triggered by the signal input from the force transducer and determines whether the force of the applicator on the tissue surface is at least a threshold pressure. In an alternative embodiment, the force detector closes a switch which sends a signal to the processing unit that a
30 pressure has been detected.

When the pressure of the applicator on the tissue surface is at least a predefined pressure, this is an indication that the microneedles are applying the requisite pressure and this is indicative of the microneedles being in the requisite position. In the case of

skin, the microneedles are applying the requisite pressure when the microneedle tips are pressed through the stratum corneum layer of the skin.

Additionally or alternatively some or all of the microneedles may be connected to a pole of the signal generator and a ground electrode applied to the tissue surface.

5 A DC or pulsatile signal of non-stimulating energy (e.g., 1 V or 2 mA) is generated by the signal generator generating an electrical signal between the microneedles and the ground electrode. The current is monitored by the processing unit and the tissue impedance is calculated from the electrical signal. A tissue impedance that is below a predetermined threshold is indicative of the formation of micropores, and that the
10 requisite pressure is being applied.

When it is determined that the requisite pressure is being applied, an ablation signal is generated by the signal generator and applied between a first subset of one or more of the microneedles, on the one hand, and a second subset of microneedles, on the other hand. The ablation signal is designed to cause ablation of the tissue
15 surrounding the microneedles in the first subset. Since tissue is elastic in nature, micropores formed by microneedles tend to partially or fully close when the microneedles are moved. In order to ensure that the micropores formed by the microneedle array remain open following removal of the microneedles the ablative electric signal is used to ensure that the micropores remain open.

20 As the ablation signal is being applied between the two subsets of microneedles, the processing unit monitors the current flowing between the microneedles of the two subsets and determines if the ablation around the microneedles in the first subset is satisfactory. Satisfactory ablation of the tissue around the microneedles reduces the overall impedance of the tissue and reduces the
25 amplitude of the treatment signal by surface electrodes needed for effective treatment.

The process is repeated one or more times with different selections of the first and second subsets of microneedles. The processing unit then determine whether the overall ablation of the tissue is satisfactory. When it is determined that ablation of the tissue region is satisfactory, the applicator is removed from the tissue surface and a
30 treatment surface electrode is placed on the tissue surface over the micropores that were formed in the tissue. A treatment signal is then generated between the treatment surface electrode passing through a second tissue underlying the tissue surface. The treatment continues as required in any application.

The system may include a communication module for wireless communication to external devices (e.g., smartphone, computer etc.) and/or to a cloud-based database server. The communication module can be used to store data (also on a cloud-based repository), for software updates, training, remote assistance, and communication
5 between the present system and a physician. The communications module can enable remote access to data and information by a health care professional who could respond and provide instructions in real time.

The system can further include sensors for measuring physiological parameters of the subject such as heart rate, blood pressure, sweat, respiration rate and
10 temperature. These parameters are analyzed to assist in determining the type and/or timing of the electrical signal delivery by the surface electrodes. For example, electrical signal delivery to the vagus nerve is known to influence the blood pressure. Sensing the blood pressure and analyzing it may affect the delivered electrical signal characteristics and timing.

A fluid analysis unit can also be incorporated into/connected to the present system to provide blood, urine, sweat or saliva chemistry. Such an analysis may have an effect on the timing and characteristics of the electrical signal delivery and the location of delivery. For example, cytokines analysis from blood samples may indicate the effectiveness of the treatment and whether there is a need to modify the electrical
15 signal characteristics and/or timing to influence the cytokines level.

The efficacy of electrical conduction from a surface electrode into a tissue through micropores depends on the quality of the micropores (e.g., depth, diameter, shape, structure etc.). The invention allows verification that micropores formed by the microneedle array have the desired characteristics. This in turn helps to maximize
20 patient comfort.

The present system can be used for aesthetic treatment (of, for example, facial skin) or to treat a variety of disorders/conditions that can benefit from electrical stimulation of, for example, muscle or nerve tissue.

The following is an incomplete list of disorders or conditions treatable by the
25 present invention.

(i) Pain relief - back pain, neuropathic pain, carpal tunnel syndrome, shoulder pain, chronic and intractable pain including diabetic neuropathy, complex regional pain syndrome, phantom limb pain, ischemic limb pain, refractory unilateral

limb pain syndrome, post-herpetic neuralgia and acute herpes zoster pain. Pain treatment can be carried out via electrical stimulation of the tibial nerve. An exemplary electrical signal can have an electrical current of 10 mA and a frequency of 100Hz.

(ii) Rehabilitation - restoring function, for example, grasping for supporting tasks of daily living. Generation of electric signal towards nerves that directly or indirectly innervate various muscles. An exemplary electrical signal can have an electrical current of 15 mA and a frequency of 50Hz.

(iii) Incontinence (fecal or urinary) and overactive bladder. An exemplary electrical signal can have an electrical current of 5 mA to 20 mA and a frequency of 20Hz.

(iv) Treatment of epilepsy, depression, Alzheimer, anxiety, obesity, bulimia, tinnitus, obsessive compulsive disorder, hypertension, or heart failure, by, for example, stimulating the neck, face, chest or stomach adjacent to the vagus nerve or one of its branches. An exemplary electrical signal can have an electrical current of 10 mA and a frequency of 10Hz.

(v) Treatment of cancer, tumors, such as prostate cancer, brain cancer, breast cancer. Treatment of cancer and tumors may be achieved in addition and/or together with chemotherapy treatment. The system and methods of this invention may enhance the chemotherapy process. An exemplary electrical signal can have an electrical current of 10 mA and a frequency of 10Hz.

(vi) Regulation of the immune system for treating autoimmune diseases, reducing systemic inflammation. An exemplary electrical signal can have an electrical current of 10 mA and a frequency of 10Hz.

(vii) Hair growth enhancement by stimulating the scalp. An exemplary electrical signal can have an electrical current of 5 mA and a frequency of 1MHz.

One specific use for the system of the present invention is treatment of disorders that benefit from vagal nerve stimulation or one of its branches. Such disorders includes, but are not limited to, substance addiction, anxiety disorders, autism, bipolar disorders, cerebral palsy, chronic headaches, cognitive impairment associated with Alzheimer disease, coma, depression, eating disorders (e.g., anorexia and bulimia), essential tremor, fibromyalgia, heart failure, hemicrania continua, juvenile myoclonic epilepsy, migraine headaches, mood disorders, narcolepsy, obesity, obsessive-compulsive disorder, sleep disorder, tinnitus and Tourette's syndrome,

hypomanic personality disorder or any other organic hypersomnia, tension type headache, alcohol-induced sleep disorders, drug-induced sleep disorders, episodic mood disorders, autistic disorder, obsessive-compulsive disorders, dysthymic disorder, alcohol dependence syndrome, drug dependence, nondependent abuse of drugs,

5 anorexia nervosa, specific disorders of sleep of nonorganic origin, unspecified disorders of eating, tension headache, circadian rhythm sleep disorder, organic parasomnia, organic sleep disorders, essential and other specified forms of tremor, hemicrania continua, infantile cerebral palsy, migraine, cataplexy and narcolepsy, rheumatic heart failure, myalgia and myositis, sleep disturbances, polyphagia, mood,

10 Parkinson's disease and headache, Achalasia, Addison's disease, Adult Still's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome, Autoimmune angioedema, Autoimmune dysautonomia, Autoimmune encephalomyelitis, Autoimmune hepatitis, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune

15 oophoritis, Autoimmune orchitis, pancreatitis, acute pancreatitis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune urticaria, Axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, Benign mucosal pemphigoid, Bullous pemphigoid, Castleman disease (CD), Celiac disease, Chagas disease, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal

20 osteomyelitis (CRMO), Churg-Strauss Syndrome (CSS) or Eosinophilic Granulomatosis (EGPA), Cicatricial pemphigoid, Cogan's syndrome, Cold agglutinin disease, Congenital heart block, Cocksackie myocarditis, CREST syndrome, Crohn's disease, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic esophagitis

25 (EoE), Eosinophilic fasciitis, Erythema nodosum, Essential mixed cryoglobulinemia, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura (HSP), Herpes

30 gestationis or pemphigoid gestationis (PG), Hidradenitis Suppurativa (HS) (Acne Inversa), Hypogammaglobulinemia, IgA Nephropathy, IgG4-related sclerosing disease, Immune thrombocytopenic purpura (ITP), Inclusion body myositis (IBM), Interstitial cystitis (IC), Juvenile arthritis, Juvenile diabetes Type 1 diabetes), Juvenile

myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus, Lyme disease chronic, Meniere's disease, Microscopic polyangiitis (MPA), Mixed connective tissue disease (MCTD), Mooren's ulcer, 5 Mucha-Habermann disease, Multifocal Motor Neuropathy (MMN) or MMNCB, Multiple sclerosis, Myasthenia gravis, Myelin Oligodendrocyte Glycoprotein Antibody Disorder, Myositis, Narcolepsy, Neonatal Lupus, Neuromyelitis optica, Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism (PR), PANDAS, Paraneoplastic cerebellar degeneration (PCD), Paroxysmal nocturnal 10 hemoglobinuria (PNH), Parry Romberg syndrome, Pars planitis (peripheral uveitis), Parsonage-Turner syndrome, Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia (PA), POEMS syndrome, Polyarteritis nodosa, Polyglandular syndromes type I, II, III, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Primary Biliary 15 Cholangitis, Primary sclerosing cholangitis, Progesterone dermatitis, Psoriasis, Psoriatic arthritis, Pure red cell aplasia (PRCA), Pyoderma gangrenosum, Raynaud's phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Relapsing polychondritis, Restless legs syndrome (RLS), Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, 20 Sjögren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome (SPS), Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia (SO), Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocytopenic purpura (TTP), Thyroid eye disease (TED), Tolosa-Hunt syndrome (THS), Transverse myelitis, Type 1 diabetes, Ulcerative colitis (UC), Undifferentiated connective tissue 25 disease (UCTD), Uveitis, Vasculitis, Vitiligo, Vogt-Koyanagi-Harada Disease, Sepsis, bleeding disorders.

The treatment could be performed by other branches of the vagus or other nerves that have influence on the diseases. Either by being connected to the vagus or to the areas that control the disease.

30 Vagus nerve stimulation may activate the body's natural inflammatory reflex to dampen inflammation and improve clinical signs and symptoms. The inflammatory reflex is a neurophysiological mechanism that regulates the body's immune system. It senses infection, tissue injury and inflammation and relays this information to the

central nervous system, which then reflexively increases neural signaling peripherally through the vagus nerve and splenic nerve that extensively innervate the spleen and other visceral organs. The signal is transmitted to T cells in the spleen, which in turn direct effector cells including monocytes and macrophages to reduce their production of the mediators that initiate and perpetuate inflammation. Inflammation plays a significant role in acute and chronic diseases including rheumatoid arthritis, inflammatory bowel disease, psoriasis, diabetes, heart disease and multiple sclerosis.

This in one of its aspects, the present invention provides a system for electrical stimulation of a body tissue comprising:

- (a) an array of microneedles, the microneedles formed from an electrically conductive material and adapted for puncturing a surface of the tissue;
- (b) a power unit
- (c) one or more surface electrodes configured to be connected to the power unit and deliver electrical stimulation to the body tissue;
- (d) a processing unit configured to determine from a signal input to the processing unit any one or more of:
 - if the microneedles in the microneedle array are in a predetermined position in the tissue; and
 - if tissue surrounding one or more microneedles has been ablated.

One or more of the surface electrodes may be wettable electrodes.

The system according of the invention may further comprise one or more force detectors, each force detector being configured to detect application of a pressure exerted by the tissue on one or more of the microneedles in the array, the pressure being indicative of a position of the microneedles in the tissue, and to generate a signal indicative of a position of one or more of the microneedles, the signal being input to the processing unit. One or more of the force detectors may comprise a displacement mechanism that activates the force detector when a force is detected by the force detector. The force detector may be a spring based detector in which an extent of compression of the spring is indicative of the pressure exerted by microneedles in the array. The force detector may also be a load cell-based force detector. One or more of the force detectors may comprise a switch that is closed

when a predetermined force is detected by the force detector, and closing of the switch generates an electric signal input to the processing unit.

The processing unit may be configured to monitor the time dependent electric signal and determining if the microneedles in the microneedle array are in a predetermined position in the tissue may involve determining when the pressure exerted by the tissue on the microneedles is above a predetermined threshold.

The system of the invention may further comprise a switching circuit configured for intermittent electrical connection of one or more selectable subsets of the microneedles to the power unit and for intermittent electrical connection of one or more of the surface electrodes to the power unit.

The system of the invention may further comprise a signal generator, and the processing unit may be further configured to activate the signal generator to deliver an electrical signal between a selectable first subset of microneedles and a selectable second subset of microneedles or between a selectable first set of microneedles and at least one of the surface electrodes. The processing unit may be further configured to activate the signal generator to deliver an ablation signal between a first selectable subset of microneedles and either a second selectable subset of microneedles and one or more of the surface electrodes, the ablation signal selected to cause ablation of the tissue surrounding one or more of the microneedles. The processing unit may be further configured to activate the signal generator to deliver the ablation signal only after the processing unit has determined that the microneedle array is in the predetermined position. The processing unit may be further configured to activate the signal generator to generate a test signal between a first selectable subset of microneedles and either a second selectable subset of microneedles and one or more of the surface electrodes, and to determine if tissue surrounding the microneedles in the first selectable subset has been ablated involves analyzing a response of the tissue to the test signal. The processing unit may be further configured to generate the test signal between a plurality of first selectable subsets of microneedles and either one or more second selectable subsets of microneedles and one or more of the surface electrodes, and to determine if ablation of the microneedles in the array meets a predetermined criterion. The processing unit may be further configured to determine a number of microneedles in the array for which tissue surrounding the microneedle has been ablated. The predetermined criterion may be that the number of

microneedles in the array for which tissue surrounding the microneedle has been ablated is above a predetermined threshold. The processing unit may be configured to deliver the electrical stimulation to the tissue when the predetermined criterion is met.

The ablation signal may be a voltage signal. The ablation signal may consist of
5 a series of wave train pulses. The ablation signal may comprise a square voltage pulses of alternating sign, or a sine wave signal. The ablation signal may have, for example, an amplitude of 200 volts to 800 volts and a frequency of 1 KHz to 1,000 KHz.

Determining if tissue surrounding the microneedles in the first selectable
10 subset has been ablated may involve monitoring a current or impedance response of the tissue and determining if the current is above a predetermined threshold or the impedance is below a predetermined threshold.

The system of the invention may be configured to deliver electrical stimulation through skin. In this case, the predetermined position of the microneedles
15 is when the microneedles have penetrated through the stratum corneum layer of the skin. The system may be configured to deliver electrical stimulation to one or more nerves under the skin surface, such as a vagus nerve.

A method for electrical stimulation of a body tissue comprising:

- (a) applying an array of microneedles to a surface of the body tissue, and
20 puncturing the tissue surface to generate micropores in the tissue;
- (b) applying one or more surface electrodes to the tissue surface over the micropores and delivering electrical stimulation through the one or more surface electrodes;
- (c) determining any one or more of:
25
 - if the microneedles in the microneedle array are in a predetermined position in the tissue; and
 - if tissue surrounding one or more microneedles has been ablated.

30 BRIEF DESCRIPTION OF THE DRAWINGS

The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of

illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.

In the drawings:

Figs. 1A-B show a system for electrical stimulation of a body tissue in accordance with one embodiment of the invention;

schematically illustrate one embodiment of the present system showing the control unit, surface electrodes and the microneedle array (Figure 1A) and the control unit and surface electrodes applied to tissue with one surface electrode mounted over the micropores formed by the microneedles array (Figure 1B);

Fig. 2 shows microneedle array that may be used in the system of Fig. 1 pressed onto a body tissue;

Figs. 3A-B show electrical current between various combinations of microneedles in the microneedle array of Fig. 2, and Fig. 3C shows the shape of an individual microneedle;

Figs. 4A-B schematically illustrate a vagus nerve stimulation procedure using the present system;

Figs. 5A-B illustrate various signal profiles for micropore verification, ablation and treatment using the present system;

Figs. 6-9 show graphs illustrating the levels of various cytokines in rats treated with the present system and rats challenged with LPS and treated with the present system;

Fig. 10 shows a graph showing changes in rat blood pressure following application of a stimulatory signal using the present system; and

Fig. 11 shows a method of electrical stimulation of a body tissue in accordance with one embodiment of this aspect of the invention.

DETAILED DESCRIPTION

The present invention provides a system and method for electrical stimulation of a body tissue, which can be used to deliver an electrical signal to tissue using one or more surface electrodes. The system of the present invention employs a microneedle array and an ablation signal for forming electrically conductive micropores in a tissue and a processing unit for verifying that the micropores formed exhibit desired electrical conductivity characteristics.

Referring now to the drawings, Fig. 1A illustrates a system **10** for electrical stimulation of a body tissue in accordance with one embodiment of the invention. The system **10** includes an applicator **13** including an array **15** of two or more microneedles **12** attached to a support **14**.

The support **14** may be fabricated, for example, from polycarbonate. The microneedles **12** are made from an electrically conductive material such as stainless steel, and, in addition to being able to puncture the tissue surface and enter the tissue, the microneedles **12** also function as electrodes, as explained in detail below. Each microneedle **12** may have a coating of an insulation material **36**, such as polycarbonate, that prevents leakage of electric current through the sides of the microneedle, promotes conduction of an electrical current to the microneedle tip **32** and creates folds **39** (Fig. 2) to enhance penetration of microneedles.

In one embodiment, each microneedle **12** has a base portion **30** (surrounded by the insulation material **36** in Fig. 1A) and a pointed tip portion **32** shaped to puncture a first tissue and penetrate into the tissue to form micropores in a superficial layer of the first tissue. The shape of the insulation material **36** may be conic, in general, (Fig. 2) with a smaller diameter near the tip portion of the microneedle **32**. The base portion **30**, may be, cylindrical, extending about 10-10,000 micrometers in length and 10-500 micrometers in diameter. When utilized for puncturing skin over a region of the vagus nerve, for example, the length of the tip portion of the microneedle **32** can be 40-150 micrometers in length. The base portion **30** may also have a shape and diameter that are different than the tip **32**. The diameter may be enlarged to allow a more stable base. For example, the microneedle may also have a non-cylindrical shape (e.g., a flat microneedle), with a width of about 40-300 micrometers and a length of about 40-8,000 micrometers and a height of extending about 10-10,000 micrometers (Fig. 3C). The microneedle array **12** may cover an area of about 0.5-5 square centimeters,

typically 0.5-2 square centimeters for placement, for example, on the neck for vagus nerve stimulation.

The microneedle array **15** can be, for example, a 16 x 16 microneedle array. The microneedles can be bonded to the support **14** or held in place by friction, for example, by being inserted into sockets in the support **14**. Alternatively, the support **14** can be fabricated integrally with the microneedles **12**, for example, using semiconductor chip fabrication technologies, well known in the art.

The system **10** further includes a control unit **22**, which includes a processing unit **25** and memory **21**, a signal generator **37**, power unit **41**, and a switching circuit **31**. The power unit **41** can include power components known in the art such as a transformer. The processing unit **25** controls the switching circuit **31**, to intermittently connect the various electrodes of the system to poles of the signal generator **37** and/or to the power unit **41** and/or to the processing unit **25** during the various stages of the treatment, as explained in detail below. The switching circuit **31** may include more than one set of switches to connect the various electrodes. For example, one set could be used to connect the microneedles **12** to the processing unit **25** and/or the signal generator **37** and/or to the power unit **41** while another set is used to connect the surface electrodes **28** to the processing unit **25** and/or the signal generator **37** and/or to the power unit **41**. The signal generator **37** may include more than one set of signal generators for the different signals. The power unit **41** may include more than one set of power units for the different signals. The control unit **22** and/or the switching circuit **31** intermittently connects a selectable first subset of microneedles **12** in the array **15** to one pole of the power unit **41** and to intermittently connect a selectable second subset of microneedles **12** in the array **15** to a second pole of the power unit **41**. The processing unit **25** can also control the signal generator **37**, to generate an electrical signal between two poles of the power unit **41**. The microneedles **12** can be connected to the switching circuit **31** via wires **24** or through a printed circuit (PCB). The components of the control unit **22** may be energized from a battery or from an external power source.

The control unit **22** may also include a display **20** and a user input device **35** such as a keypad or a touch screen which may be integral with the display **20**. The input device **35** may be used to program the processing unit **25** to drive the switching circuit **31** and the signal generator **37** to generate an electric signal between selected

first and second subsets of microneedles **12** and to generate an electric signal between selected first and second surface electrodes **28** having desired characteristics with regard, for example, to the frequency, electrical potential, and profile of the signal. The control unit **22** may also include a communication unit **42** to allow a remote control of the control unit **22**, for example by Bluetooth.

The applicator **13** may include a force detector **16** that detects pressure applied to the tissue surface by the tips **32** of the microneedles **12** as the applicator **13** is pressed into the tissue surface during penetration of the microneedles **12** into the tissue. The microneedle array **15** may include a displacement mechanism that activates the force detector **16** when the microneedles **12** are pressed onto the tissue. The force detector **16** may generate a time dependent electric signal indicative of the pressure that is input to the processing unit **25**. The force detector **16** can be a spring based transducer in which an extent of compression of the spring is indicative of the pressure applied to the tissue surface. Alternatively, the force transducer **16** may be a load cell-based transducer. The load-cell transducer may be connected to the display **20** of system **10** to provide an indication of a force applied by tip/s **32**. A galvanic separation between the microneedles **12** and the control unit **22** may be maintained until a predefined force has been applied by the tip/s **32**. The applicator **13** may include more than one set of force detectors **16**. The force can be measured collectively or at each microneedle. A predefined force applied on the force detector may be a trigger for initiation of the ablation signal by microneedles **12**, and also for verification that at least the predefined force is applied during the delivery of the ablation signal to the first tissue.

The system **10** further comprises a treatment surface electrode **28** and a ground surface electrode **26**. The electrodes **26** and **28** are surface electrodes connected to the switching circuit **31** via wires **27** and **29**, respectively. Wires **27** and **29** may include more than one wire each to connect to more than one surface electrode **26** and more than one surface electrode **28**. The electrodes **26** and **28** can be dry, wet or wettable electrodes. A conductive liquid, such as saline can be used to wet the electrode surface. The saline may have a concentration, for example, between 0.1%-25%, preferably in the range of 5%-15%. The electrodes **26** and **28** can have any shape and dimensions as required in any application. For example, the electrodes **28** and **26** may be a 2 X 2 cm square with a width of 0.5 centimeters, or any other dimension and

shape suitable for the desired treatment region, such as a circle or oval. The electrodes **26** and **28** can be disposable or reusable, and can include an adhesive surface for attachment to a first tissue (e.g., skin). The processing unit **25** controls the switching circuit **31** to intermittently connect two or more surface electrodes **28** to the poles of the power unit **41** and/or the signal generator **37**. The processing unit **25** also controls the switching circuit **31** to connect one or more surface electrodes **26** to the poles of the power unit **41** and/or the signal generator **37**.

Fig. 11 shows a flow chart for a method of electrical stimulation of a tissue, using the system of the present invention, in accordance with one embodiment of the invention. In step **50**, the applicator **13** is applied to a first tissue surface on top of a second tissue region to be treated. The second tissue may be a nerve, but not limited, that is located relatively deep (e.g., more than 0.5 centimeter, may also be less deep as well) under the surface of the first tissue (e.g., skin). Fig. 4A shows, as an example, the placement of the applicator **13** on the neck of an individual over the vagus nerve in a treatment for stimulating the vagus nerve (the vagus nerve may be located at a depth of more than 1 centimeter under the skin). As pressure is applied by the applicator **13**, the force detector **16** detects a pressure applied to the tissue surface and generates an electrical signal indicative of the pressure that is input to the processing unit **25**. The processing unit **25** constantly monitors or is triggered by the signal input from the force transducer **16** (step **52**) and determines whether the force of the applicator **13** on the tissue surface is at least a threshold pressure that was previously stored in a memory of the processing unit (step **54**). In an alternative embodiment, not shown, when a pressure on the tissue surface is detected by the force detector **16**, the force detector **16** closes a switch which sends a signal to the processing unit **25** that a pressure has been detected. As shown in Fig. 2, pressure of the applicator **13** on the tissue surface can cause the tissue to create deformations **39** and be inserted into the spaces between the microneedles **12** and its coating **36**. This deformation has been found to be helpful for microneedle **12** penetration into the superficial layer of the first tissue and may also reduce the pressure needed for insertion of the microneedles through the tissue surface.

If the pressure of the applicator **13** on the tissue surface has not yet reached the predefined pressure, the pressure of the applicator on the tissue surface is increased (step **56**) and the process returns to step **52**. When the pressure of the applicator **13** on

the tissue surface is at least the predefined pressure, this is an indication that the microneedles **12** are applying the requisite pressure and the process can proceed to step **58**. The inventors have found that a pressure in the range of 0.3 to 2 kg/cm², but typically in the range of 0.5 to 1.2 kg/cm², is indicative of the microneedles being in the requisite position. In the case of skin, the microneedles **12** are applying the requisite pressure when the microneedle tips **32** are pressed through the stratum corneum layer of the skin.

Additionally or alternatively some or all of the microneedles **12** may be connected to a pole of the signal generator **37** via the switching circuit **31**, and the ground electrode **26** applied to the tissue surface and connected to another pole of the signal generator **37** via the switching circuit **31**. A DC or pulsatile signal of non-stimulating energy (e.g., 1 V or below 2 mA) is generated by the signal generator **37** generating an electrical signal between the microneedles **12** and the ground electrode **26**. The current is monitored by the processing unit **25** and the tissue impedance is calculated from the electrical signal. A tissue impedance that is below a predetermined threshold is indicative of the formation of micropores, and that the requisite pressure is being applied.

When it is determined that the requisite pressure is being applied, an index *k* is set to 1, and a counter is set to 0 (step **58**). This is only an example and other methods known in the art to measure time and activate switching circuit may be used. Now, in step **60**, a *k*th subset1 of microneedles in the microneedle array **15** and a *k*th subset2 of microneedles in the microneedle array **15** (previously stored in the memory **21**) are recalled from the memory **21** of the control unit **22**. The *k*th subset1 and the *k*th subset2 are non-empty disjoint sets of microneedles. The microneedles in the *k*th subset1 are then connected to a first pole of the signal generator **37** and/or power unit **41** via the switching circuit **31** and the microneedles in the *k*th subset2 are then connected to another pole of the signal generator **37** and/or power unit **41** via the switching circuit **31** (step **62**).

In an alternate embodiment, a *k*th subset2 is not used, and instead, the ground electrode **26** is attached to the second pole of the signal generator.

The process now continues with step **64** where a *k*th ablation signal, generated by the signal generator **37** is applied between the microneedles in the *k*th subset1, on the one hand, and the microneedles in the *k*th subset2, on the other hand. The *k*th

ablation signal is designed to cause ablation of the tissue surrounding the microneedles in subset1. Fig. 3A shows schematically, as a first example, part of the microneedle array **15** having 6 microneedles. In the example of Fig. 3A, microneedle **12a** is the sole microneedle in the kth subset1. The remaining five microneedles, microneedles **12b** to **12f** constitute the kth subset2. The dashed curves in Fig. 3A indicate an electrical signal between microneedle **12a** and each of the microneedles in the kth subset2, upon application of the ablation signal to the first tissue. Fig. 3B shows schematically, as a second example, part of the microneedle array **15** having 6 microneedles in which the microneedle **12g** together with microneedle **12h** constitute kth subset1. The remaining four microneedles, microneedles **12i** to **12l** constitute the kth subset2. The dashed curves in Fig. 3B indicate an electric signal between microneedles **12g** and **12h** and each of the microneedles in the kth subset2, upon application of the ablation signal. This is only an example and any permutation of subset1 and subset2 are allowed.

Fig. 5, upper panel, shows an example of an ablation signal applied between the microneedles in the kth subset1 and the microneedles in the kth subset2 to the first tissue. The ablation signal shown in the upper panel of Fig. 5 is a voltage signal consisting of a series of wave train pulses, where each pulse consists of a number of square voltage pulses of alternating sign. The square shape is only an example and other shapes could be used (e.g., a sine waveform can also be used). Depending on the tissue being treated, each pulse would typically have an amplitude of 25 V to 2,000 V (typically 200-800v), and a frequency of 1 KHz to 1,000 KHz.

The pulse trains of the ablation signal are applied during time intervals of duration t_1 , t_3 , t_5 , etc. These times may be predefined or determined on the fly, but typically, the duration times of the pulses are between 1-20 milliseconds. The pulses are separated by periods of quiescence of duration t_2 , t_4 , etc. when the ablation signal is not applied and when impedance can be measured.

Referring again to Fig. 11, as the kth ablation signal is being applied between the kth subset1 and subset2, the pressing unit monitors the current flowing between the one or more of the microneedles in the kth subset1 and one or more of the microneedles in the kth subset2 (step **66**). The bottom panel of Fig. 5 shows a typical current response to an ablation signal such as the ablative voltage signal shown in the upper panel. As the ablation progresses, the current rises indicating a decrease in the

tissue impedance, penetration of the microneedles through the tissue, and the ablation process. The current reaches a peak and then decays. While not wishing to be bound by any particular theory, it is believed that at the current peak and then during the decay of the current, ablative tissue that is less conductive surrounds the microneedle.

5 This may be an indication of the state of the micropore.

Then, in step **68**, the processing unit **25** determines if the ablation around one or more of the microneedles in the k th subset1 is satisfactory. Satisfactory ablation of the tissue around the microneedles reduces the overall impedance of the tissue and reduces the amplitude of the treatment signal by surface electrodes **28** needed for
10 effective treatment.

In one embodiment, the ablation around the microneedles in subset1 is determined to be satisfactory when the height of the peak in the current response is above a predetermined threshold level (indicated by the horizontal dashed line in the bottom panel, and previously stored in the memory **27**). In another embodiment, a
15 change (e.g., reduction) in the phase of the signal is used to determine if the ablation is satisfactory. If the ablation around the microneedles in the k th subset1 is satisfactory, the counter, which counts the number of microneedles whose surrounding tissue has been satisfactorily ablated, is increased by the number of microneedles in the k th subset1. (step **70**).

20 The process now proceeds to step **72** where it is determined whether k is equal to a maximum value $k_{\max}$, where $k_{\max}$ is the number of pairs of subset1 and subset2 which are to be examined for the ablation of surrounding tissue. If k is not equal to $k_{\max}$, then in step **74** k is increased by 1 and the process returns to step **60** where subset1 and subset2 for the new value of k is recalled from the memory **27**. If $k=k_{\max}$,
25 the process continues to step **76** where it is determined whether the overall ablation of the tissue is satisfactory. This is determined from the final value of the counter which counts the number of microneedles for which ablation of the surrounding tissue was found to be satisfactory. Overall ablation of the tissue may be considered satisfactory, for example, when the number of microneedles for which ablation of the surrounding
30 tissue was found to be satisfactory is above a predetermined threshold. Otherwise, overall tissue ablation would not be considered to be satisfactory. The threshold may be, for example, a predetermined fraction, such as 0.8, of the number of microneedles in the array **15**, (i.e. the overall ablation of the tissue is satisfactory when the ablation

around at least 80% of the microneedles is satisfactory). When it is determined that ablation of the tissue region is not satisfactory, the applicator may be moved to a new location on the tissue surface (step **78**) and the process can return to step **52** and begin again with the applicator at the new location. In another example not shown, another location for generation of micropores may be chosen for creation of micropores. The process of micropores creation could be performed in more than one location to allow placement of more than one surface electrode **28** over micropores (not included in Fig. 11).

If, at step **76**, it is determined that ablation of the tissue region is satisfactory, the applicator **13** is removed from the tissue surface (step **80**) and the treatment electrode **28** is placed on the tissue surface over the micropores that were formed in the tissue (step **82**). The quality of the treatment requires good alignment of the surface electrode **28** with the formed micropores. This can be accomplished, for example, by marking the tissue surface with the boundaries of the area of the tissue surface to be treated, and applying the microneedle array **15** (step **50**) and the treatment electrode **28** (step **82**) within the boundary markings. Another method for assuring alignment of the treatment electrode **28** with the micropores makes use of a device, described in US Patent 10,688,301 having an aperture covered by a removable flap on which the treatment electrode **28** is incorporated. The device is adhered to the tissue surface with the aperture over the area of the tissue surface to be treated. The flap can be lifted or removed to reveal the skin surface under the aperture. The microneedle array **15** can be pressed into the tissue surface through the aperture of the patch, and the micropores thus formed can then be ablated and the microneedle array **15** removed and the flap, can then be closed to bring the surface electrode **28** into contact with the skin surface directly over the formed micropores. In another example the aperture does not include a flap, and the surface electrode is separate from the flap.

Fig. 1B shows the system **10** with the treatment electrode **28a** and another electrode **28b** placed on the tissue surface with the treatment electrode **28a** over the micropores **33** that were formed in the first tissue. This is only an example and micropores could be created under surface electrode **28b** as well. The micropores **33** can extend 10-300 micrometers (but not limited) into the tissue and in the case of skin preferably extend through the highly resistive keratinized layer. Fig. 4B shows, again as an example, the placement of the surface electrodes **28a** and **28b** on the neck of an

individual in a treatment for stimulating the vagus nerve. A treatment procedure to modify the levels of cytokines is initiated by selecting the target vagus nerve (left and/or right along the neck of the subject) then marking the location for two surface electrodes **28** to be placed over the tissue surface over the vagus nerve with a suitable distance between electrodes (e.g., 1-10 cm). Other treatments such as hypertension could be performed as well, by other electrical signal parameters for treatment. The treatment electrode **28a** is positioned over the micropores that were formed in the tissue over the vagus nerve (cf Fig. 4A). A treatment signal **44** is then generated between the surface electrode **28a** passing through a second tissue such as the vagus nerve and the surface electrode **28b** (step **84**). The presence of the micropores under the electrode **28a** tends to direct the current through deeper layers of the tissue, such as the vagus nerve in the arrangement shown in Fig.4B. Fig 5B illustrates the waveform of two exemplary electrical signals that may be used in the electrical stimulation of the tissue. These signals can be voltage or current controlled with a current of 0.1 mA - 50 mA, a voltage of 0.1 V - 100 V and a frequency of 1-1M Hz. The pulse duration can vary from 10-1,000 microseconds (typical 50-500 microseconds).

The process ends with the completion of the treatment.

Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non-limiting fashion.

EXAMPLE 1

Rat Cytokine Study

The effect of electrical stimulation on pro- and anti- inflammatory cytokines was studied using a rat model and a prototype of the present system.

Thirty adult rats were divided to four groups:

(i) lipopolysaccharide (LPS);

- (ii) lipopolysaccharide (LPS) + electrical stimulation treatment; and
- (iii) electrical stimulation treatment only; and
- (iv) control.

5 Lipopolysaccharide from *Escherichia coli* (LPS, 5mg/kg body weight) was administrated via injection to the rat at time 0 minutes (Figs 6-9) and blood samples were collected 30 minutes before the LPS administration and 90 and 120 minutes following the LPS administration.

10 Electrical stimulation was performed using a tissue stimulating system of the present invention having a microneedle array with 80-160 microneedles and a surface area of 0.5-1.5 square centimeters) for generation of micropores and measurement of tissue characteristics and two wettable surface electrodes 0.5-2.0 centimeters in diameter for the delivery of the electrical stimulation and impedance measurement, and

15 Prior to treatment, the rat was shaved in an area of the neck with a hair trimmer while taking care not to break the skin surface. The treatment location was determined anatomically on the neck of the rat, over the vagus nerve and the insertion location of the microneedle array was marked on the skin. Tissue characteristics prior to and following micropore generation were monitored as described hereinabove.

20 Micropores were generated by pressing the microneedle array into the skin in the marked area of the skin surface over the vagus nerve. After insertion of the microneedle array into the skin, it was determined as described above, that the microneedles are in the requisite position with the microneedle tips having passed through the stratum corneum. The tissue surrounding each microneedle was then ablated as determined above, and the microneedle array removed from the skin surface. A treatment surface electrode was applied to the skin surface over the micropores and a ground electrode was placed 1-10 centimeters away from the treatment electrode.

The rats in groups ii and iii were treated with a stimulatory signal having the following parameters:

- 30 Frequency - 5-30 Hz
- Pulse width - 100-500 microseconds
- Pulse shape - Bi polar
- Interphase - 10-100 microseconds

Intensity Range - 1.0-4.0 mA

Groups ii and iii were treated with 2 sessions of 10 minutes each.

Groups iii was not administered with LPS.

5 Groups iv was not administrated with LPS and was not electrically treated.

The results are shown in Figs 6-9. Figs 6-8 describe the average measurement of the cytokines TNF α , IL6, IL-1 β , respectively, and Fig 9 describes an average measurement of IL-10 at 90 minutes and 120 minutes following administration of LPS. The bars indicate standard deviation.

10 (IL-1 β : 145 pg/ml, and 770 pg/ml; IL6: below sensitivity level, 852 pg/ml; TNF α : 105 pg/ml, 565 pg/ml; IL-10: below sensitivity level, below sensitivity level) are of Group i and bars 3 and 4 (IL-1 β : 20 pg/ml, 214 pg/ml; IL6: below sensitivity level, 364pg/ml; TNF α : below sensitivity level, 280 pg/ml; IL-10: 53 pg/ml, 713 pg/ml) are of Group ii. Groups iii and iv were below detection sensitivity. The
15 statistical calculations showed a reduction of the level of the TNF α , IL6, IL-1 β cytokines in Group ii which was significant with $p < 0.05$, and an increase of the level of the IL-10 in Group ii which was also significant with $p < 0.05$.

EXAMPLE 2

20 *Rat Blood Pressure Study*

The effect of electrical stimulation on rat blood pressure was studied on four rats using a system of the invention. After the formation of micropores in the skin of the neck, as described above, a stimulatory surface electrode was placed over the micropores and the vagus nerve was stimulated with a signal having the following
25 parameters:

Frequency - 10-40 Hz

Pulse width - 200-1000 microseconds

Pulse shape - Bi polar

Interphase - 10-100 microseconds

30 Intensity Range - 0.5-4.0 mA

Fig. 10 shows the average systolic and diastolic blood pressure of the four rats showing an average baseline obtained over a 50 minute period prior to treatment. This was followed by the above treatment for 5 minutes, and then by 45 minutes of blood

pressure monitoring. The systolic pressure decreased by 15% during the measurement period following treatment and the diastolic pressure decreased by about 20% during the same time period.

It is appreciated that certain features of the invention, which are, for clarity,
5 described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

Although the invention has been described in conjunction with specific
10 embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by reference
15 into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention.

CLAIMS

1. A system for electrical stimulation of a body tissue comprising:
 - (a) an array of microneedles, the microneedles formed from an electrically conductive material and adapted for puncturing a surface of the tissue;
 - 5 (b) a power unit
 - (c) one or more surface electrodes configured to be connected to the power unit and deliver electrical stimulation to the body tissue;
 - (d) a processing unit configured to determine from a signal input to the processing unit any one or more of:
 - 10 * if the microneedles in the microneedle array are in a predetermined position in the tissue; and
 - * if tissue surrounding one or more microneedles has been ablated.
2. The system according to claim 1 further comprising one or more force detectors, each force detector being configured to detect application of a pressure exerted by the tissue on one or more of the microneedles in the array, the pressure being indicative of a position of the microneedles in the tissue, and to generate a signal indicative of a position of one or more of the microneedles, the signal being input to the processing unit.
3. The system according to claim 2 wherein one or more of the force detectors comprise a displacement mechanism that activates the force detector when a force is detected by the force detector.
4. The system according to claim 2 or 3 wherein the force detector is a spring based detector in which an extent of compression of the spring is indicative of the pressure exerted by microneedles in the array.
- 25 5. The system according to claim 2 or 3 wherein the force detector is a load cell-based force detector.
6. The system according to any one of claims 2 to 5 wherein one or more of the force detectors comprises a switch and the switch is closed when a predetermined force is detected by the force detector, and closing of the switch generates an electric signal input to the processing unit.
- 30

7. The system according to claim 6 wherein the processing unit is configured to monitor the time dependent electric signal and wherein determining if the microneedles in the microneedle array are in a predetermined position in the tissue involves determining when the pressure exerted by the tissue on the microneedles is above a predetermined threshold.
8. The system according to any one of the previous claims further comprising a switching circuit configured for intermittent electrical connection of one or more selectable subsets of the microneedles to the power unit and for intermittent electrical connection of one or more of the surface electrodes to the power unit.
9. The system according to claim 8 further comprising a signal generator, and the processing unit is further configured activate the signal generator to deliver an electrical signal between a selectable first subset of microneedles and a selectable second subset of microneedles or between a selectable first set of microneedles and at least one of the surface electrodes.
10. The system according to claim 9 wherein the processing unit is further configured to activate the signal generator to deliver an ablation signal between a first selectable subset of microneedles and either a second selectable subset of microneedles and one or more of the surface electrodes, the ablation signal selected to cause ablation of the tissue surrounding one or more of the microneedles.
11. The system according to claim 10 wherein the processing unit is further configured to activate the signal generator to deliver the ablation signal only after the processing unit has determined that the microneedle array is in the predetermined position.
12. The system according to claim 10 or 11 wherein the processing unit is further configured to activate the signal generator to generate a test signal between a first selectable subset of microneedles and either a second selectable subset of microneedles and one or more of the surface electrodes, and to determine if tissue surrounding the microneedles in the first selectable subset has been ablated involves analyzing a response of the tissue to the test signal.
13. The system according to claim 11 wherein the processing unit is further configured to generate the test signal between a plurality of first selectable

subsets of microneedles and either one or more second selectable subsets of microneedles and one or more of the surface electrodes, and to determine if ablation of the microneedles in the array meets a predetermined criterion.

- 5 **14.** The system according to claim 13 wherein the processing unit is further configured to determine a number of microneedles in the array for which tissue surrounding the microneedle has been ablated.
- 15.** The system according to claim 14 wherein the predetermined criterion is that the number of microneedles in the array for which tissue surrounding the microneedle has been ablated is above a predetermined threshold.
- 10 **16.** The system according to claim 14 or 15 wherein the processing unit is configured to deliver the electrical stimulation to the tissue when the predetermined criterion is met.
- 17.** The system according to any one of the claims 10 to 16 wherein the ablation signal is a voltage signal.
- 15 **18.** The system according to claims 10 to 17 wherein the ablation signal consists of a series of wave train pulses.
- 19.** The system according to any one of claims 10 to 18 wherein the ablation signal comprises square voltage pulses of alternating sign.
- 20.** The system according to any one of claims 10 to 19 wherein the ablation
20 signal comprises a sine wave signal.
- 21.** The system according to any one of claims 10 to 20 wherein the ablation signal has an amplitude of 200 volts to 800 volts.
- 22.** The system according to any one of claims 10 to 21 wherein the ablation signal has a frequency of 1 KHz to 1,000 KHz.
- 25 **23.** The system according to any one of claims 18 to 22 wherein determining if tissue surrounding the microneedles in the first selectable subset has been ablated involves monitoring a current or impedance response of the tissue and determining if the current is above a predetermined threshold or the impedance is below a predetermined threshold.
- 30 **24.** The system according to any one of the previous claims configured to deliver electrical stimulation through skin.

25. The system according to claim 24 wherein in the predetermined position of the microneedles in the microneedle array, the microneedles have penetrated through the stratum corneum layer of the skin.
26. The system according to claim 24 or 25 wherein the system is configured to deliver electrical stimulation to one or more nerves under the skin surface.
27. The system according to claim 26 wherein the nerve is a vagus nerve.
28. The system according to any one of claims wherein one or more of the surface electrodes are wettable electrodes.
29. A method for electrical stimulation of a body tissue comprising:
- (a) applying an array of microneedles to a surface of the body tissue, and puncturing the tissue surface to generate micropores in the tissue;
 - (b) determining any one or more of:
 - if the microneedles in the microneedle array are in a predetermined position in the tissue; and
 - if tissue surrounding one or more microneedles has been ablated; and
 - (c) applying one or more surface electrodes to the tissue surface over the micropores and delivering electrical stimulation through the one or more surface electrodes;

FIG. 1A




FIG. 1B




FIG. 2




FIG. 3A




FIG. 3B







FIG. 3C









FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11 (Beginning)





FIG. 11 (Cont)



INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL2022/051156

A. CLASSIFICATION OF SUBJECT MATTER A61N 1/04 (2023.01)i; A61N 1/05 (2023.01)i; A61N 1/32 (2023.01)i; A61N 1/36 (2023.01)i; A61B 18/14 (2023.01)i; A61B 18/08 (2023.01)i CPC:A61N 1/0412; A61N 1/0456; A61N 1/04; A61N 1/0504; A61N 1/327; A61N 1/36017; A61B 18/1477; A61B 18/082 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61N 1/04; A61N 1/05; A61N 1/32; A61N 1/36; A61B 18/14; A61B 18/08 CPC:A61N 1/0412; A61N 1/0456; A61N 1/04; A61N 1/0504; A61N 1/327; A61N 1/36017; A61B 18/1477; A61B 18/082 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Databases consulted: Google Patents, Orbit, Similari (AI-based)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2013023749 A1 (NELLCOR PURITAN BENNETT LLC [US]; AFANASEWICZ ELIZABETH A [US]; HARHEN ROBERT P [US]; YOUNG ADAM J [US]; CORDERO RAFAEL M [US]; POWERS GERALD [US]) 24 January 2013 (2013-01-24) the whole document especially para. [0032],[0061], [0065], [0071], [0075]	1-7,24-29
X	US 2010241181 A1 (SAVAGE WALTER T [US]; SAVAGE SHELLEY J [US]; MACLAY WALTER N [US]; MORRISON DOUGLAS C [US]; GERATY THOMAS K [US]; BRINKERHOFF MARK D [US]; BOEDER RONALD S [US]; TON TONY M [US]; GREGER JEFFREY S [US]; CARDIOTHRIVE INC [US]) 23 September 2010 (2010-09-23) the whole document especially para. [0072], figs 8, 12	1-7,26-29
A	US 10688301 B2 (SOLOMON SASI [IL]; SYNAPSTIM LTD [IL]) 23 June 2020 (2020-06-23) the whole document	1-29
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents: “A” document defining the general state of the art which is not considered to be of particular relevance “D” document cited by the applicant in the international application “E” earlier application or patent but published on or after the international filing date “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) “O” document referring to an oral disclosure, use, exhibition or other means “P” document published prior to the international filing date but later than the priority date claimed “T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention “X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone “Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art “&” document member of the same patent family		
Date of the actual completion of the international search 09 March 2023		Date of mailing of the international search report 12 March 2023
Name and mailing address of the ISA/IL Israel Patent Office Technology Park, Bldg.5, Malcha, Jerusalem, 9695101, Israel Israel Telephone No. 972-73-3927214 Email: pctoffice@justice.gov.il		Authorized officer LEVI Moria Telephone No.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/IL2022/051156

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
US	2013023749	A1	24 January 2013	US	2013023749	A1	24 January 2013
				US	9131900	B2	15 September 2015
US	2010241181	A1	23 September 2010	US	2010241181	A1	23 September 2010
				US	8615295	B2	24 December 2013
				CN	102427851	A	25 April 2012
				CN	102427851	B	15 April 2015
				EP	2408521	A2	25 January 2012
				EP	2408521	A4	08 August 2012
				EP	2408521	B1	25 June 2014
				EP	2788075	A1	15 October 2014
				EP	2788075	A4	29 July 2015
				EP	2788075	B1	25 April 2018
				JP	2012520738	A	10 September 2012
				JP	5563652	B2	30 July 2014
				JP	2015500090	A	05 January 2015
				JP	5894678	B2	30 March 2016
				US	2012310315	A1	06 December 2012
				US	8781576	B2	15 July 2014
				US	2014324113	A1	30 October 2014
				US	9101778	B2	11 August 2015
				US	2018200528	A1	19 July 2018
				US	11311716	B2	26 April 2022
				US	2014039593	A1	06 February 2014
				US	2014039594	A1	06 February 2014
				WO	2010107707	A2	23 September 2010
				WO	2010107707	A3	13 January 2011
				WO	2013085702	A1	13 June 2013
US	10688301	B2	23 June 2020	US	2017209695	A1	27 July 2017
				US	10688301	B2	23 June 2020
				AU	2015370443	A1	16 March 2017
				AU	2015370443	B2	09 April 2020
				AU	2020204495	A1	23 July 2020
				AU	2020204495	B2	08 October 2020
				BR	112017001479	A2	05 December 2017
				BR	112017001479	B1	06 December 2022
				CA	2991689	A1	30 June 2016
				CN	107206234	A	26 September 2017
				CN	107206234	B	11 May 2021
				EP	3171932	A1	31 May 2017
				EP	3171932	A4	20 June 2018
				EP	3171932	B1	13 April 2022
				EP	4011439	A2	15 June 2022
				EP	4011439	A3	12 October 2022
				ES	2922982	T3	22 September 2022
				IL	250250	B	01 February 2022
				JP	2017523015	A	17 August 2017
				JP	7018313	B2	10 February 2022
				KR	20170086461	A	26 July 2017
				KR	102406800	B1	08 June 2022
				WO	2016103245	A1	30 June 2016